The complaint, filed following a disastrous Q2 2026 earnings report, alleges that Embecta misled the market by characterizing its pen needle portfolio as resilient even as the company faced significant market headwinds. Throughout the class period, leadership repeatedly touted the durability of these devices—which account for more than 70% of total revenue—to support an adjusted EPS guidance of $2.80 to $3.00. Investors claim these statements were reckless given the undisclosed vulnerabilities in the sector.

Expectations cratered on May 5, 2026, when Embecta reported an adjusted EPS of $0.27, marking a 61% decline. The company subsequently slashed its annual earnings guidance by roughly 43% and reduced its dividend by 93% to a penny per share. Hagens Berman, the firm leading the investigation, is now scrutinizing when management became aware of these revenue declines and whether they were sufficiently transparent with the public. Reed Kathrein, a partner at the firm, noted the investigation focuses on the company's failure to communicate risks that ultimately shattered investor confidence.